G12C/G12V KRAS mutation in PC & CRC patients respond to Pela Testing treatments for advanced pancreatic cancer
New treatments for metastatic pancreatic cancer that are being investigated in clinical trials include immunotherapy and targeted therapy. Immunotherapy uses substances to stimulate or suppress the immune system to help the body fight cancer. Targeted therapy uses drugs or other substances to target specific molecules that cancer cells need to survive and spread.
- Targeted therapies
- Ras-directed therapies. The RAS genes makes proteins that take part in signaling pathways that control cell growth. Altered forms of these genes are found in more than 90% of pancreatic cancers. Drugs that target mutant forms of RAS are now being tested. One example is a drug that targets a form of RAS that has a mutation called G12C and another drug that targets a more common mutation, G12D.
https://www.cancer.gov/types/pancreatic/research More than half the CRC patients that responded to pelareorep had either a G12V or a G12D mutation (exon 2, codon 12, KRAS gene). https://aacrjournals.org/mct/article/19/5/1148/274337/Elucidation-of-Pelareorep-Pharmacodynamics-in-A Pelareorep (Reolysin) is an unmodified oncolytic reovirus, delivered intravenously, that can induce a T-cell inflamed phenotype in pancreatic ductal adenocarcinoma. In a phase Ib study in patients who had progressed after first-line treatment, pelareorep, pembrolizumab, and 5-fluorouracil, irinotecan, or gemcitabine did not add significant toxicity and showed encouraging efficacy. ( https://pubmed.ncbi.nlm.nih.gov/31694832/ ) https://ascopubs.org/doi/full/10.1200/EDBK_389072